As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
13 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:
13 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 251 251 |
65%
65%
|
|
| Gross Profit | 237 237 |
66%
66%
|
|
| EBITDA | 62 62 |
22%
22%
|
|
| EBIT (Operating Income) EBIT | 29 29 |
64%
64%
|
|
| Net Profit | 49 49 |
8%
8%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
| Head office | United States |
| CEO | Todd Davis |
| Employees | 68 |
| Founded | 1987 |
| Website | www.ligand.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


